Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glycopyrronium + tropisetron
- Development stage
- Phase 4
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intramuscular, Inhalation, Topical
01
Overview
A combination of glycopyrronium (an anticholinergic agent) and tropisetron (a 5-HT3 receptor antagonist used as an antiemetic). Glycopyrronium is used to treat hyperhidrosis, severe drooling, COPD, and as an adjunct in treating ulcers, while tropisetron is used to prevent chemotherapy-induced nausea and vomiting.
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)CHRM4 (M4)CHRM5 (M5)
Beyond the preview
Go deeper on glycopyrronium + tropisetron.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glycopyrronium + tropisetron.